Online inquiry

IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4804MR)

This product GTTS-WQ4804MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets DPP4 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001379604.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1803
UniProt ID P27487
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4804MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8164MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ15436MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ12802MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ9682MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ8187MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ5100MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ3039MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ1358MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-874
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW